Treatment of infected aortic aneurysm or vascular graft infection with a rifampicin-bonded gelatin-sealed Dacron graft
Not Applicable
Recruiting
- Conditions
- infected aortic aneurysm, vascular graft infection
- Registration Number
- JPRN-UMIN000022379
- Lead Sponsor
- Kyoto Prefectural University of Medicine Cardiovascular Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
(1) patients with allergic for rifampicin (2) patients who refuse to the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method clinical control of infection (imaging study and/or laboratory study)
- Secondary Outcome Measures
Name Time Method patient death
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie rifampicin-bonded gelatin-sealed Dacron graft efficacy in infected aortic aneurysm treatment?
How does rifampicin-bonded Dacron graft compare to standard-of-care for vascular graft infections in clinical outcomes?
Are there specific biomarkers that predict successful patient selection for gelatin-sealed Dacron graft treatment in aortic infections?
What are the potential adverse events associated with rifampicin-bonded gelatin-sealed grafts and how are they managed?
What combination therapies or alternative antibiotics show promise in treating infected vascular grafts alongside Dacron grafts?